Table 4 Postremission outcome of APL... | American Society of Hematology

Table 4

Postremission outcome of APL patients in the PETHEMA LPA99 and LPA2005 trials

Characteristic	No. of patients		CIR			DFS			OS
Characteristic	Overall	CR, n (%)	% at 3 y	% at 4 y	P	% at 3 y	% at 4 y	P	% at 3 y	% at 4 y	P
Overall	963	883 (92)	8	11		88	85		87	85
All patients
LPA99	561	511 (91)	9	11	.39	87	84	.06	85	83	.08
LPA2005	402	372 (92)	7	9		92	90		89	88
Low-risk
LPA99	107	103 (96)	4	4	.58	90	89	.49	91	89	.14
LPA2005	84	83 (99)	6	6		93	93		96	96
Intermediate-risk
LPA99	313	294 (94)	5	7	.69	91	87	.21	89	88	.18
LPA2005	200	191 (95)	6	8		94	92		93	91
High-risk
LPA99	140	113 (81)	26	27	.03	73	71	.11	71	68	.34
LPA2005	118	98 (83)	11	14		82	82		79	79

Characteristic	No. of patients		CIR			DFS			OS
Characteristic	Overall	CR, n (%)	% at 3 y	% at 4 y	P	% at 3 y	% at 4 y	P	% at 3 y	% at 4 y	P
Overall	963	883 (92)	8	11		88	85		87	85
All patients
LPA99	561	511 (91)	9	11	.39	87	84	.06	85	83	.08
LPA2005	402	372 (92)	7	9		92	90		89	88
Low-risk
LPA99	107	103 (96)	4	4	.58	90	89	.49	91	89	.14
LPA2005	84	83 (99)	6	6		93	93		96	96
Intermediate-risk
LPA99	313	294 (94)	5	7	.69	91	87	.21	89	88	.18
LPA2005	200	191 (95)	6	8		94	92		93	91
High-risk
LPA99	140	113 (81)	26	27	.03	73	71	.11	71	68	.34
LPA2005	118	98 (83)	11	14		82	82		79	79

CIR indicates cumulative incidence of relapse; CR, complete response, DFS, disease-free survival; and OS, overall survival.